Sanofi Blocks Novartis’ Branded Jevtana Rival in Patent Case Win

Sanofi won a ruling blocking Novartis AG’s Sandoz unit from selling its branded copy of Jevtana until a patent for the prostate cancer treatment expires more than seven years from now.

“On the whole, I find that a healthcare provider reading Defendant’s label would be encouraged to administer cabazitaxel for the specific purpose of increasing a patient’s survival,” Judge Richard G. Andrews wrote in an opinion issued June 26 in the US District Court for the District of Delaware. Cabazitaxel is the drug’s active ingredient.

“It seems to me that a healthcare provider reading Defendant’s label would not think to ...